Bristol Myers Squibb (BMS) has entered a strategic agreement with AI safety and research company Anthropic to deploy Claude across multiple enterprise functions, including research, manufacturing, clinical development, regulatory operations, and commercial workflows.
Under the collaboration, BMS will focus on integrating Anthropic’s AI capabilities into three core operational areas: embedding Claude Code within engineering and data science teams, incorporating AI agents into enterprise workflows, and connecting Claude to the company’s institutional knowledge systems.
The deployment is intended to support research activities across oncology, neuroscience, hematology, and immunology. According to the company, research teams will use Claude to help identify and optimize drug targets, while development teams will apply the technology to automate trial documentation and regulatory submission processes.
BMS also plans to utilize Claude within manufacturing operations. Applications will include root-cause investigations, Corrective and Preventive Action (CAPA) documentation, and data-driven batch release decisions. Commercial and medical affairs teams are expected to use the technology to support engagement with healthcare professionals and other operational activities.
The company stated that Anthropic’s AI platform will be integrated across scientific, clinical, regulatory, and commercial functions to provide access to institutional knowledge with enterprise governance and audit controls in place.
“Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos, and this collaboration is how we reach it,” Greg Meyers, EVP and chief digital and technology officer at Bristol Myers Squibb, said in a statement.
“Anthropic’s Claude gives us the agentic capabilities, pace of innovation and security necessary to connect our systems and put that collective knowledge in the hands of every BMS employee to accelerate innovation for patients. The companies that lead the next decade of biopharma will be the ones that learn to operate fundamentally differently with AI, and BMS intends to be one of them.”
The agreement reflects a broader trend across the pharmaceutical industry toward enterprise-scale AI adoption. Several life sciences organizations have recently announced collaborations with AI companies to support drug discovery, clinical development, manufacturing, and commercial operations.
Recent examples include OpenAI’s partnerships with Novo Nordisk, Sanofi, Moderna, and Thermo Fisher Scientific, as well as AI-enabled drug discovery agreements involving Isomorphic Labs, Novartis, Eli Lilly, Owkin, and AstraZeneca.
Click here for the original news story.